|
|
Genzyme is committed to helping your patients achieve their PTH goals, If you and your patient are not satisfied with the results achieved with Hectorol 1 mcg capsules, Genzyme promises to pay the out-of-pocket cost* for the first prescription of another medication for SHPT. Please see terms and Conditions for full details of this offer.
For more information on the Hectorol Start Card, call RenassistSM at 1-800-847-0069.
Hectorol 1 mcg Promise* Terms and Conditions
- Patient must have private health insurance that covers medication costs for Hectorol 1 mcg or have no private health insurance coverage.
- Patient must use the Hectorol Start Card for 3 months to qualify for the Hectorol 1 mcg Promise.
- Program only applies to patients who are no longer on Hectorol treatment.
- Patient (or healthcare professional) must contact 1-888-412-0647 within 30 days of finishing the third month of his/her Hectorol 1 mcg treatment to receive a Hectorol 1 mcg Promise Form and to activate the Promise.
- Patients must provide a copy of:
A Hectorol 1 mcg Promise form signed by his/her treating physician
The receipt for the product to which he/she is switching
- *Patient will receive up to $100 toward his/her out-of-pocket cost for the first prescription to manage his/her secondary hyperparathyroidism (calcitriol, paricalcitol, cinacalcet) if he/she is not satisfied after 3 months of treatment on Hectorol 1 mcg.
- Offer applies to out-of-pocket cost only.
- Program good through July 31, 2010.
- Void where prohibited by law.
Patient must not be participating in Medicare, Medicaid, TRICARE, VA, or other government-funded healthcare programs.
Patients cannot be a resident of Massachusetts.
- This is a limited-time offer. Genzyme reserves the right to rescind, revoke, amend, or terminate this offer, or the program in its entirety, at any time.
* Promise applies to 1 mcg strength only. Does not apply to 0.5 mcg and 2.5 mcg strengths.
hec_m_safety_info
Important Treatment Considerations
Hectorol is indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 Chronic Kidney Disease (capsules) and in patients with Chronic Kidney Disease on dialysis (capsules and injection). Hectorol is contraindicated in patients with a tendency towards hypercalcemia or current evidence of vitamin D toxicity. Overdosage of any form of vitamin D is dangerous. Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs. Chronic hypercalcemia can lead to generalized vascular and soft tissue calcification. Pharmacologic doses of vitamin D and its derivatives should be withheld during Hectorol treatment to avoid possible additive effects and hypercalcemia. Magnesium-containing antacids and Hectorol should not be administered concomitantly. Adverse effects of Hectorol treatment are: hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of iPTH. Adverse events reported by ≥ 5% of the Hectorol-treated predialysis patients included: infection, chest pain, constipation, dyspepsia, anemia, dehydration, depression, hypertonia, insomnia, paresthesia, increased cough, dyspnea, and rhinitis. Adverse events reported by ≥ 5% of the Hectorol-treated dialysis patients included: headache, malaise, bradycardia, nausea/vomiting, edema, dizziness, dyspnea, and pruritus. See Hectorol Capsules Full Prescribing Information or Hectorol Injection Full Prescribing Information or call Genzyme Medical Information at 1-800-847-0069.
|
|
 |
|
|
|
| Contact |
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email Us
|
 |
|
|
|
|
